WeVote
Log In

Bill

Bill

HD 2523

An Act relative to benzodiazepines and non-benzodiazepine hypnotics

194th Legislature (2025-2026) Introduced by Paul McMurtry

Massachusetts bill regulating benzodiazepine and hypnotic prescribing through controls and monitoring to reduce dependency and misuse risks.

0
WeVote Research Nonpartisan
Bill Summary · HD 2523

Legislative bill overview

HD 2523 establishes new regulations and controls on benzodiazepines and non-benzodiazepine hypnotics (such as Z-drugs like zolpidem) in Massachusetts. The bill aims to address concerns about prescription practices, dependency risks, and potential misuse of these commonly prescribed sedative medications through enhanced monitoring, prescriber education, and patient protections.

Why is this important

Benzodiazepines and sedative-hypnotics carry significant risks of dependency, overdose, and adverse health outcomes, particularly when used long-term or combined with opioids. Massachusetts, like other states, has experienced rising concerns about prescription drug misuse and the role these medications play in overdose deaths, making regulatory reform a public health priority.

Potential points of contention

  • Prescriber impact: Healthcare providers may face additional administrative burdens, documentation requirements, or restrictions on prescribing practices, potentially affecting their ability to treat patients with legitimate sleep disorders or anxiety
  • Patient access concerns: Stricter controls could limit availability for patients with genuine medical need, particularly elderly patients or those with documented sleep disorders who depend on these medications
  • Scope clarity: The specific provisions (dosage limits, duration restrictions, prior authorization requirements, mandatory tapering protocols) aren't detailed here, but these details will determine whether regulations are proportionate or overly restrictive

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.